Alkermes Reports Strong Q2 Revenue, Widens Full-Year GAAP Net Loss Guidance, and Announces CEO Transition

summarizeSummary

Alkermes reported strong Q2 revenue growth, but updated full-year guidance with a wider GAAP net loss and lower EBITDA, alongside a planned CEO transition.

check_boxKey Events · Earnings and Guidance · ALKS

• Q2 Financial Results

  Total revenues increased to $496.0 million, with proprietary net sales reaching $411.7 million, driven by strong performance from LUMRYZ ($96.6 million). GAAP net income was $0.5 million, down from $87.1 million in Q2 2025.

• Updated Full-Year Guidance

  The company maintained its full-year revenue guidance but widened its GAAP net loss expectation to ($95) – ($115) million (from ($70) – ($90) million) and lowered its EBITDA guidance to $75 – $95 million (from $105 – $135 million). Adjusted EBITDA guidance remained unchanged.

• CEO Transition

  Richard Pops will transition from CEO to Chairman of the Board on August 1, 2026, with Blair Jackson, current Chief Operating Officer, assuming the role of Chief Executive Officer.

• Contingent Consideration Adjustment

  A non-cash increase of $26.4 million in the fair value of contingent consideration was recorded. This relates to the Avadel acquisition CVR milestone, which is now deemed more likely to be achieved following positive LUMRYZ Phase 3 results, increasing the accounting liability.

auto_awesomeAnalysis · ALKS · Life Sciences

Alkermes plc reported strong second-quarter revenues driven by proprietary product sales, particularly LUMRYZ. However, the company widened its full-year GAAP net loss guidance and lowered its EBITDA expectations, indicating increased costs or lower profitability than previously projected. Additionally, the long-serving CEO, Richard Pops, will transition to Chairman, with Blair Jackson taking over as CEO, marking a significant leadership change.